US Researchers Suggest Stopping Prescribing Hydroxychloroquine For Treatment And Prevention Of Covid-19 Infection

Kathleen Kinder
Kathleen Kinder

Updated · Sep 6, 2021

SHARE:

Scoop.market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us Scoop, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Scoop. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

There has been a buzz around the use of Hydroxychloroquine to bolster the fight against Covid-19 infection. The United States had last year cleared the drug for the treatment and prevention of Covid infection. But the latest study has now said that the drug is not helpful in the recovery of hospitalized patients. In fact, it can cause harm. The drug is mainly used during the treatment or prevention of malaria and a few auto-immune conditions. It was approved by the FDA. Hospitals in the country started prescribing Hydroxychloroquine for Covid treatment after some results showed that it could provide relief. This pushed the demand for the drug. Notably, America is the worst affected country by the infection.

Florida Atlantic University researchers said that more than 560,000 prescriptions have been issued alone in the country this year. The prescriptions are for the treatment, prevention, and post-exposure of Covid-19. In 2020, around 890,000 prescriptions were issued. The figures are almost nine times greater than in past years. Researchers said that they reviewed how the drug reacts. The meta-analysis showed that there was a lack of benefit in the hospitalized patients. Researchers added that the drug’s safety profile in patients is also low. The new data hinted at some potential harm as well.

Notably, the US researchers had in 2020 issued a petition for a moratorium on the prescription of the medicine. The plea said that the drug is helpful in the treatment and prevention. However, it noted that the final outcome of ongoing trials was pending. Researchers said that the latest findings support the debate for halting prescribing hydroxychloroquine for treatment and prevention of Covid-19 infection. The study even said that premature and avoidable deaths will more likely happen if the medicine is consumed for Covid-19 treatment. It added that vaccinations and masking are the powerful strategies that should be in the focus in the fight against Covid-19. Researchers concluded that the medicine did not provide the degree of respiratory failure.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over four years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.